KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Clinical trial NCT05254184 · RECRUITING
Trial details
- NCT number
- NCT05254184
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2027-04-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.